MacroGenics (MGNX) to Release Quarterly Earnings on Tuesday

Key Points

• MacroGenics will report Q1 2026 results before the market opens on May 12, with analysts forecasting ($0.56) EPS and $16.29 million in revenue; an earnings call is scheduled for May 15 at 4:00 PM ET.
• The company beat estimates in its last quarter (reported ($0.22) EPS vs. consensus ($0.42)) but analysts still expect about -1 EPS for the current and next fiscal years, with a consensus rating of "Hold" and a $5.40 price target (B. Riley and Barclays have recently raised their targets).
• MGNX traded around $3.14 (down ~2%) with a market cap near $199 million and a 1‑year range of $1.18–$3.88, while institutional ownership is very high at 96.89% amid recent stake increases from firms like Invesco, XTX and Quadrature.

MacroGenics (NASDAQ:MGNX - Get Free Report) is anticipated to issue its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.56) per share and revenue of $16.29 million for the quarter. Parties may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Friday, May 15, 2026 at 4:00 PM ET.

MacroGenics (NASDAQ:MGNX - Get Free Report) last released its earnings results on Monday, March 9th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.42) by $0.20. MacroGenics had a negative net margin of 49.91% and a negative return on equity of 120.19%. The firm had revenue of $41.23 million during the quarter, compared to the consensus estimate of $27.81 million. On average, analysts expect MacroGenics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

MacroGenics Trading Down 2.0%

MGNX traded down $0.07 during trading on Tuesday, hitting $3.14. 159,921 shares of the company's stock were exchanged, compared to its average volume of 996,487. MacroGenics has a 1 year low of $1.18 and a 1 year high of $3.88. The stock has a 50 day moving average price of $2.89 and a 200 day moving average price of $2.07. The firm has a market cap of $199.26 million, a P/E ratio of -2.68 and a beta of 1.08.

Analysts Set New Price Targets

Several research firms have issued reports on MGNX. B. Riley Financial upgraded shares of MacroGenics from a "neutral" rating to a "buy" rating and boosted their price objective for the stock from $3.00 to $9.00 in a research note on Friday, April 10th. Citigroup reiterated a "market perform" rating on shares of MacroGenics in a research note on Tuesday, February 24th. Wall Street Zen upgraded shares of MacroGenics from a "sell" rating to a "hold" rating in a research note on Saturday, March 14th. Finally, Barclays boosted their price objective on shares of MacroGenics from $4.00 to $6.00 and gave the stock an "overweight" rating in a research note on Monday, April 20th. Three research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, MacroGenics has a consensus rating of "Hold" and a consensus price target of $5.40.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Invesco Ltd. boosted its stake in shares of MacroGenics by 31.6% in the fourth quarter. Invesco Ltd. now owns 111,121 shares of the biopharmaceutical company's stock valued at $179,000 after purchasing an additional 26,668 shares during the period. Mackenzie Financial Corp purchased a new position in shares of MacroGenics in the fourth quarter valued at $324,000. XTX Topco Ltd boosted its stake in shares of MacroGenics by 38.2% in the fourth quarter. XTX Topco Ltd now owns 240,327 shares of the biopharmaceutical company's stock valued at $387,000 after purchasing an additional 66,368 shares during the period. Quadrature Capital Ltd boosted its stake in shares of MacroGenics by 521.5% in the fourth quarter. Quadrature Capital Ltd now owns 265,465 shares of the biopharmaceutical company's stock valued at $427,000 after purchasing an additional 222,751 shares during the period. Finally, Amundi purchased a new position in shares of MacroGenics in the fourth quarter valued at $345,000. 96.89% of the stock is currently owned by hedge funds and other institutional investors.

MacroGenics Company Profile

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody–based therapeutics for the treatment of cancer and autoimmune diseases. The company leverages proprietary Fc engineering technologies to enhance immune engagement and extend the activity of its antibodies. Since its founding in 2000, MacroGenics has advanced several product candidates through clinical trials, most notably margetuximab, a HER2-targeted antibody designed to improve outcomes in patients with HER2-positive breast cancer.

Central to MacroGenics' research platform are its ADAPTIR and Trident bispecific antibody technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.